Purchase Order 75N91021P00930
Award Date
9/30/21
Potential Completion Date
6/29/23
Potential Value
$142K
Federal Agency
National Cancer Institute
Ultimate Awardee
Not listed
NAICS Category
621511 - Medical Laboratories
PSC Category
Q301 - Reference Laboratory Testing
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Not Competed under SAP
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Spain
Solicitation Procedures
Simplified Acquisition
Number Of Offers Received
1
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
The Department of Health and Human Services National Institutes of Health National Cancer Institute awarded a $24,102.75 firm fixed price contract to 10X Genomics, Inc. for single cell RNA sequencing on provided RNA samples. 10X Genomics will perform the requested 5' prime single cell RNA sequencing services at their Pleasanton, California facility between February 2nd and 28th, 2023. The National Cancer Institute seeks to advance cancer research and this contract will provide genomic analysis...
The Department of Health and Human Services National Institutes of Health National Cancer Institute awarded a $3 million firm fixed price purchase order to 10X Genomics, Inc. for genomics products and services. As the prime contractor, 10X Genomics will deliver its genome sequencing platforms and assays to support the agency's cancer research efforts from its Pleasanton, California location through the end of 2023. No subcontractors or set aside designations were indicated. This award draws on...
This is a firm fixed-price delivery order contract awarded by the National Cancer Institute (NCI), part of the U.S. Department of Health and Human Services, to Fundacio De Recerca Clinic Barcelona-Institut D'investigacions Biomediques August Pi I Sunyer, a non-profit organization and foundation in Spain. The $6,000 contract is for the provision of tissue samples and data from various types of cancer to support the Cancer Genome Atlas (TCGA) program, which is a joint effort between the National...
This is a $109,080.00 firm-fixed-price purchase order awarded by the National Cancer Institute (NCI), part of the National Institutes of Health (NIH), to Novogene Corp Inc., a minority-owned small business. The contract is for long non-coding RNA and small RNA sequencing services to identify RNA biomarkers for radiation biodosimetry. The work includes sample preparation, sequencing, and data analysis for 216 mRNA/lncRNA samples and 96 small RNA samples. This effort builds on prior successful...
This contract was awarded by the National Cancer Institute (NCI), a civilian agency under the Department of Health and Human Services, to Illumina, Inc., a for-profit manufacturer of genomic sequencing and analysis solutions. The contract, valued at $35,959.68, is for the delivery of biological kits and has a completion date of April 30, 2025. It is a firm fixed-price delivery order contract with no set-aside designation. Illumina, a leading provider of genomic sequencing technologies, has...
The National Cancer Institute, a component of the National Institutes of Health within the Department of Health and Human Services, awarded a $395,850 firm fixed price purchase order to Illumina, Inc. of San Diego, California. The contract calls for Illumina to provide two Illumina NextSeq2000 Next Generation Benchtop High-Throughput Sequencing Instruments or equivalent equipment to support genomic research at NCI facilities. The solicitation sought quotes for the sequencing instruments to...
The National Cancer Institute, a component of the Department of Health and Human Services' National Institutes of Health, awarded a $22,259 firm fixed price blanket purchase agreement call contract to 10X Genomics, Inc. for reagents and consumables. 10X Genomics will provide the requested products to support the NCI's biomedical research efforts from its location in Pleasanton, California over a one week period concluding on September 6, 2023. As one of the largest funders of cancer research...
This is a $274,036 fixed-price task order awarded to the New York Genome Center, Inc. (Nygc) by the National Cancer Institute (NCI) under the NCI Genomic Characterization Centers master IDIQ contract. The purpose is to provide DNA methylation arrays to support new studies by the Cancer Genomics Program over a 3-year period of performance from September 2020 to September 2023. This task order is fully funded and non-severable. Nygc is a nonprofit academic research institution that provides...
The National Cancer Institute awarded a $2.1 million delivery order to the New York Genome Center, Inc., doing business as Nygc, against the NCI Genomic Characterization Centers master IDIQ contract. This task order, with a period of performance from August 2019 through August 2020, supports NCI's Center for Cancer Genomics program through genomic characterization services. As the prime contractor, Nygc will leverage its expertise in genomic analysis to further the NIH's mission of understanding...
The National Cancer Institute (NCI) awarded a $1,498,043 Firm Fixed Price Delivery Order contract to the University of North Carolina at Chapel Hill (UNC-CH) for the Genome Characterization Center RNA Sequencing Indefinite Delivery/Indefinite Quantity (IDIQ) Contract. This multiple-award IDIQ contract enables UNC-CH to provide comprehensive genome sequencing and analysis capabilities, including high-throughput DNA sequencing, RNA sequencing, epigenetic characterization, and single-cell/nuclei...